Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | RBP4 | P02753 | 1/20 | 0.32 |
| ▸ | F2R | P25116 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL345627 | 1.00 | TACR3 (0.37) | TACR3ITGB3ITGA2BAKR1C3SPR | |
| SCHEMBL1898526 | 0.88 | ITGB3 (0.38) | ITGB3ITGA2BHDAC3HDAC4HDAC1 | |
| SCHEMBL15608041 | 0.84 | TACR3 (0.39) | TACR3ITGB3ITGA2BSPRDPP8 | |
| SCHEMBL13740833 | 0.84 | TACR3 (0.39) | TACR3ITGB3ITGA2BSPRDPP8 | |
| SCHEMBL13739301 | 0.84 | TACR3 (0.39) | TACR3ITGB3ITGA2BSPRDPP8 | |
| SCHEMBL14737804 | 0.84 | — | — | |
| SCHEMBL2337182 | 0.82 | AKR1C3 (0.46) | TACR3ITGB3ITGA2BAKR1C3SPR | |
| SCHEMBL2337183 | 0.82 | AKR1C3 (0.46) | TACR3ITGB3ITGA2BAKR1C3SPR | |
| SCHEMBL4523791 | 0.82 | AKR1C3 (0.46) | TACR3ITGB3ITGA2BAKR1C3SPR | |
| SCHEMBL20771839 | 0.81 | CHRM2 (0.43) | TACR3ITGB3ITGA2BAKR1C3SPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358670-B1 | A process for the preparation of tert-butyl (R)-3-vinylpyrrolidine-1-carboxylate and intermediates therefor | TARGACEPT INC (US) | 2012-10-24 | — | — | EP | claimed |
| EP-2364307-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | Targacept Inc. (US) | 2011-09-14 | — | — | EP | claimed |
| EP-2358670-A2 | Novel compounds | Targacept Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| EP-2358705-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | Targacept Inc. (US) | 2011-08-24 | — | — | EP | claimed |
| WO-2010065449-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| WO-2010065443-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | claimed |
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210371401-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2021-12-02 | — | — | US | disclosed |
| US-10919879-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | Oyster Point Pharma, Inc. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200207740-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC. | 2020-07-02 | — | — | US | disclosed |
| EP-3279195-B1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | OYSTER POINT PHARMA INC (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-2358670-A2 | Novel compounds | Targacept Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| EP-2358670-A2 | Novel compounds | Targacept Inc. (US) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010065447-A3 | A PROCESS FOR THE PREPARATION OF TERT-BUTYL (R) - 3 -VINYLPYRROLIDINE- I - CARBOXYLATE AND INTERMEDIATES THEREFOR | TARGACEPT, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010065449-A1 | (R) -3- (E) -2- (PYRR0LIDIN-3-YL) VINYL) -5- (TETRAHYDR0PYRAN-4-YL0XY) PYRIDINE, ITS SALTS, ITS SYNTHESIS AND ITS USE AS LIGAND FOR NICOTINIC ACETYLCHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065443-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| WO-2010065447-A2 | NOVEL COMPOUNDS | TARGACEPT, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371401-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | TACR3 1700/4885ITGB3 4619/4885ITGA2B 4690/4885 |
| US-10919879-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | TACR3 1700/4885ITGB3 4619/4885ITGA2B 4690/4885 |
| US-20200207740-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | TACR3 1700/4885ITGB3 4619/4885ITGA2B 4690/4885 |
| US-20230295126-A1 | SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-PYRROLIDIN-3-YLVINYL)PYRIMIDINE | DPYD, DHPS, NUDT5 | TACR3 1700/4885ITGB3 4619/4885ITGA2B 4690/4885 |
| US-11542253-B2 | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine | DPYD, DHPS, NUDT5 | TACR3 1700/4885ITGB3 4619/4885ITGA2B 4690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.